PETA International Science Consortium Ltd., Society Building, 8 All Saints Street, London N1 9RL, England.
Biotechnol Adv. 2015 Dec;33(8):1787-98. doi: 10.1016/j.biotechadv.2015.10.004. Epub 2015 Oct 19.
Affinity reagents are essential tools in both basic and applied research; however, there is a growing concern about the reproducibility of animal-derived monoclonal antibodies. The need for higher quality affinity reagents has prompted the development of methods that provide scientific, economic, and time-saving advantages and do not require the use of animals. This review describes two types of affinity reagents, recombinant antibodies and aptamers, which are non-animal technologies that can replace the use of animal-derived monoclonal antibodies. Recombinant antibodies are protein-based reagents, while aptamers are nucleic-acid-based. In light of the scientific advantages of these technologies, this review also discusses ways to gain momentum in the use of modern affinity reagents, including an update to the 1999 National Academy of Sciences monoclonal antibody production report and federal incentives for recombinant antibody and aptamer efforts. In the long-term, these efforts have the potential to improve the overall quality and decrease the cost of scientific research.
亲和试剂是基础研究和应用研究中必不可少的工具;然而,人们越来越关注动物源性单克隆抗体的可重复性。对高质量亲和试剂的需求促使人们开发了一些方法,这些方法具有科学、经济和节省时间的优势,并且不需要使用动物。本文综述了两种亲和试剂,即重组抗体和适体,它们是非动物技术,可以替代动物源性单克隆抗体的使用。重组抗体是基于蛋白质的试剂,而适体是基于核酸的。鉴于这些技术的科学优势,本文还讨论了如何在科学研究中采用现代亲和试剂,包括更新 1999 年美国国家科学院的单克隆抗体生产报告和联邦对重组抗体和适体研究的激励措施。从长远来看,这些努力有可能提高科学研究的整体质量并降低成本。